Deletion(20q) as the sole abnormality in plasma cell myeloma is not associated with plasma cells as identified by cIg FISH

Cancer Genetics

Volumn 205, Issue 12, 2012, Pages 644-652

  White, Joanne S ^a   Zordan, Adrian ^a   Batzios, Crisoula ^a   Campbell, Lynda J ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Deletion of 20q; FISH; Plasma cell myeloma

Indexed keywords

CYTOPLASMIC IMMUNOGLOBULIN; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL TYPE; CHROMOSOME 20Q; CHROMOSOME 5; CHROMOSOME 9; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ASSOCIATION; HUMAN; INTRACELLULAR SIGNALING; KARYOTYPE; MALE; MOLECULAR PROBE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CELL NUCLEUS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; CYTOPLASM; DNA PROBES; FEMALE; HUMANS; IMMUNOGLOBULINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 84872024046     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.10.007     Document Type: Article

References (28)

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
2. Rajkumar S.V. Multiple myeloma. Curr Probl Cancer 2009, 33:7-64.
3. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
4. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007, 20:625-635.
5. Sawyer J.R. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011, 204:3-12.
6. Debes-Marun C.S., Dewald G.W., Bryant S., et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003, 17:427-436.
7. Jacobson J.B.B., Shaughnessy J., Drach J., et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003, 122:430-440.
8. Schmetzer H.M., Mittermüller J., Duell T., et al. Development of myeloma and secondary myelodysplastic syndrome from a common clone. Cancer Genet Cytogenet 1998, 100:31-35.
9. Březinová J., Zemanová Z., Ransdorfová Š., et al. Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 2005, 160:188-192.
10. Liu Y.-C., Miyazawa K., Sashida G., et al. Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. Cancer Genet Cytogenet 2006, 169:69-72.
11. Barlogie B., Tricot G., Haessler J., et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 2008, 111:94-100.
12. Slovak M.L., Bedell V., Pagel K., et al. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization. Cancer Genet Cytogenet 2005, 158:99-109.
13. Nilsson T., Nilsson L., Lenhoff S., et al. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer 2004, 41:223-231.
14. Crescenzi B., La Starza R., Sambani C., et al. Totipotent stem cells bearing del(20q) maintain multipotential differentiation in Shwachman Diamond syndrome. Br J Haematol 2009, 144:116-119.
15. White N., Nacheva E., Asimakopoulos F., et al. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood 1994, 83:2809-2816.
16. Steensma D.P., Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003, 27:95-120.
17. Steensma D.P., Dewald G.W., Hodnefield J.M., et al. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. Leuk Res 2003, 27:235-242.
18. Campbell L.J., White J.S. Cytogenetic analysis in acute myeloid leukaemia. Cancer Cytogenetics Methods and Protocols 2011, 63-77. Humana Press, New York. L.J. Campbell (Ed.).
19. ISCN 2009: An International System for Human Cytogenetic Nomenclature 2009, Karger, Basel. L.G. Shaffer, M.L. Slovak, L.J. Campbell (Eds.).
20. Mercer B.R., Rayeroux K.C. Detection of chromosome abnormalities using cytoplasmic immunoglobulin staining and FISH in myeloma 2011, 159-171. Humana Press, New York. L.J. Campbell (Ed.).
21. Ross F.M., Avet-Loiseau H., Ameye G., et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 2012, 97:1272-1277.
22. Garayoa M., Garcia J.L., Santamaria C., et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009, 23:1515-1527.
23. Arnulf B., Lecourt S., Soulier J., et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007, 21:158-163.
24. Streubel B., Chott A., Huber D., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004, 351:250-259.
25. Sahota S.S., Stevenson F.K. Lineage complexity in multiple myeloma?. Leuk Lymphoma 2006, 47:1997-1998.
26. Rigolin G.M., Fraulini C., Ciccone M., et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006, 107:2531-2535.
27. Ghosh N., Matsui W. Cancer stem cells in multiple myeloma. Cancer Lett 2009, 277:1-7.
28. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.